An in vivo model of chemosensitization of multidrug resistant human myeloma cell line in SCID mice

Bellamy, William; Odeleye, A; Finley, Paul R.; Huizenga, B; Dalton, William S.; Weinstein, R. S.; Grogan, Thomas M.

doi:10.1097/00001813-199409001-00035

Cited by 10 publications

(12 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, once weekly injection at a higher dose was superior in its anti-multiple myeloma effects compared with 3 times weekly (on consecutive days) at lower doses. In contrast, the toxicity of single-agent doxorubicin at 2 mg/kg, when administered once weekly, resulted in the deaths of all mice after only 3 injections, which is consistent with prior studies (45,46). As expected, the addition of bortezomib to doxorubicin or PLD at the MTD dose (2 mg/kg), which is the equivalent of the doxorubicin dose used in the INNO-206 (2.7 mg/kg) plus bortezomib studies, was also not tolerated in these mice and all animals were dead by day 28.…”

Section: Discussionsupporting

confidence: 89%

Anti-Myeloma Effects of the Novel Anthracycline Derivative INNO-206

Sanchez

Li²,

Wang³

et al. 2012

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: Doxorubicin has shown efficacy especially in combination treatment for the treatment of multiple myeloma; however, its side effects limit its use. INNO-206 is an albumin-binding prodrug of doxorubicin, which is released from albumin under acidic conditions. Because INNO-206 has not been previously evaluated in any hematologic malignancy, we determined its anti-multiple myeloma effects.Experimental Design: The anti-multiple myeloma effect of at different pH levels on multiple myeloma cell proliferation using multiple myeloma cell lines with the MTS assay and antiangiogenic activity using the chorioallantoic membrane/feather bud assay were determined. The anti-multiple myeloma effects and toxicity of INNO-206 were also compared with conventional doxorubicin and PEGylated liposomal doxorubicin (PLD) alone, and in combination with bortezomib, using our multiple myeloma xenograft models.Results: INNO-206 inhibited blood vessel formation and reduced multiple myeloma cell growth in a pHdependent fashion. INNO-206 alone produced marked anti-multiple myeloma effects in vivo at doses that doxorubicin was toxic, and the combination of INNO-206 plus bortezomib produced increased antimultiple myeloma effects compared with either agent alone. In contrast, all mice receiving bortezomib with doxorubicin or PLD died.Conclusions: These findings show that INNO-206 produces anti-multiple myeloma effects in vitro and in vivo. It also enhances the antitumor effects of bortezomib. These results suggest that INNO-206 may provide patients with multiple myeloma with an anthracycline that may be administered safely at higher doses compared with free doxorubicin, resulting in superior efficacy compared with the currently available anthracyclines to treat this B-cell malignancy.

show abstract

Section: Discussionsupporting

confidence: 89%

Anti-Myeloma Effects of the Novel Anthracycline Derivative INNO-206

Sanchez

Li²,

Wang³

et al. 2012

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…Previously, other investigators developed MM models by injecting MM cell lines into SCID-NOD mice. [3][4][5][6][7][8][9][10][11] A recently developed model also exploited the advantages of fluorescence-based optical imaging, which has a high resolution for GFP imaging and also allows frequent and serial non-invasive monitoring. 28,29 While highly useful and convenient, an important drawback of this recent model was the extramedullary growth of tumors, which is not a typical feature of MM.…”

Section: Discussionmentioning

confidence: 99%

“…To date, three xenograft models of human myeloma have been developed: SCID-Hu, [3][4][5] NOD/SCID, [6][7][8][9][10] and SCID-Rab. 11 While these models offer several opportunities to test therapeutics in vivo against human myeloma, each of them also has reported limitations, in particular for reproducible, convenient and sensitive monitoring of cellular immunological therapies in combination with immunomodulatory agents.…”

Section: Introductionmentioning

confidence: 99%

A bioluminescence imaging based in vivo model for preclinical testing of novel cellular immunotherapy strategies to improve the graft-versus-myeloma effect

Rozemuller¹,

Spek²,

Bogers-Boer³

et al. 2008

Haematologica

View full text Add to dashboard Cite

show abstract

“…SCID mice were found to be a more suitable model for studying liver métas tasés of human colon cancer than nude mice [26]. However, the growth pattern of a cell line in SCID mice depends on the route of inoculation and the dose of injected cells [27], Subcutaneous inoculation enabling evalua tion of tumour progress results in a quite high xenograft take rate, although some authors found the highest take with the intraperitoneal route [28],…”

Section: Discussionmentioning

confidence: 99%

Tumoricidal Activity of Antiseptics with Assessment of Cell Viability in Mice with Severe Combined Immunodeficiency

Basha¹,

Penninckx²,

Geboes³

et al. 1997

Tumor Biol

View full text Add to dashboard Cite

Previously, we have assessed the efficacy of different cytotoxic agents on the viability of SW620 human colonic carcinoma cells in vitro. In this study, we have investigated the tumoricidal efficacy of some antiseptic agents on SW620 human colonic carcinoma cells which were subsequently inoculated into severe combined immunodeficient (SCID) mice. An inoculum of 5 × 10⁶ cells suspended in 200 μl buffer solution was found to be the minimum number of cells needed to result in tumour growth within 8 weeks after subcutaneous injection into SCID mice. The integrity of the cells was assessed in vitro with the trypan blue exclusion test after 30 min incubation in distilled water (DW), chloramine 0.5% in DW and polyvinyl pyrrolidone iodine (PVP-I) 0.01, 0.05, 0.1 and 5% in DW. DW and PVP-I 0.01% were not tumoricidal, neither in vitro nor in vivo. In contrast, PVP-I 5% and chloramine 0.5% ‘killed’ all or almost all tumour cells in vitro and prevented their growth in vivo. PVP-I 0.05 and 0.1% were less effective in vitro than 5 %, but could prevent in vivo proliferation unless an adjustment of the residual number of viable tumour cells was performed. These data indicate the importance of the amount of the tumour inoculum and hence the need to use a maximally effective ‘killing’ agent.

show abstract

An in vivo model of chemosensitization of multidrug resistant human myeloma cell line in SCID mice

Cited by 10 publications

References 0 publications

Anti-Myeloma Effects of the Novel Anthracycline Derivative INNO-206

Anti-Myeloma Effects of the Novel Anthracycline Derivative INNO-206

A bioluminescence imaging based in vivo model for preclinical testing of novel cellular immunotherapy strategies to improve the graft-versus-myeloma effect

Tumoricidal Activity of Antiseptics with Assessment of Cell Viability in Mice with Severe Combined Immunodeficiency

Contact Info

Product

Resources

About